New shorter radiation course aims to ease sarcoma treatment for seniors
NCT ID NCT06022159
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a shorter, higher-dose radiation therapy given over one week before surgery for soft tissue sarcoma in patients aged 70+ or those 65+ who are considered fragile. The goal is to see if this approach reduces major wound complications after surgery. About 48 participants will receive the radiation followed by surgery and be monitored for up to 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hypofractionated radiation therapy (IMRT)
What this could lead to
If successful, this shorter radiation course could become a standard option for older or fragile sarcoma patients, reducing treatment burden and wound healing problems.
What could go wrong
This is a small, early-phase study with only 48 participants and no comparison group. The shorter radiation schedule may still cause wound complications or fail to control the cancer as well as standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Leon Berard
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Limoges
RECRUITINGLimoges, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Poitiers
RECRUITINGPoitiers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Toulouse
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IUCT-O
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Bergonie
RECRUITINGBordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Curie
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Regional Du Cancer de Montpellier
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancerologie de L'Ouest
RECRUITINGSaint-Herblain, France
Contact Phone: •••-•••-•••• Email: •••••@•••••